Your TL;DR: The new NIH SBIR/STTR Parent NOFOs allow clinical trials, but not for every participating Institute, Center, or FDA component. Applicants whose projects include a clinical trial and align only with certain NIH or FDA organizations may find their applications deemed non-responsive and removed from review before scientific merit is ever considered. Understanding where clinical trials are accepted and where they are not has become a critical part of the submission strategy.
A Submittable NIH Application Is Not Necessarily a Reviewable Application
One of the more important details buried within the newly released NIH SBIR/STTR Parent NOFOs has nothing to do with budgets, due dates, or eligibility. It concerns whether a clinical trial is permitted at all.
The Parent NIH NOFOs continue to allow applications that include clinical trials. Many applicants will understandably read that language and assume their project is eligible if it otherwise aligns with NIH priorities. The reality is more complicated. Several participating Institutes, Centers, and FDA components explicitly state that they do not accept clinical trials through these Parent NOFOs. Applications proposing a clinical trial that align only with one of these organizations are considered non-responsive and will not be reviewed. Before investing significant effort into proposal development, it may be worth evaluating whether your target Institute or Center accepts the type of work you intend to propose.
Which Components Do Not Accept Clinical Trials Under the NIH Parent NOFO?
Applications proposing clinical trials are not responsive to the Parent NOFO when they align exclusively with the mission of the following organizations:
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Center for Advancing Translational Sciences (NCATS)
- Office of Research Infrastructure Programs (ORIP)
- All participating FDA components, including:
- Center for Biologics Evaluation and Research (CBER)
- Center for Drug Evaluation and Research (CDER)
- Human Foods Program (HFP)
- Center for Devices and Radiological Health (CDRH)
- Center for Veterinary Medicine (CVM)
This distinction matters because the issue is not whether the science is compelling. The issue is whether the application fits the funding mechanism being used.
The GAP: Many Companies Will Discover This Too Late
A recurring challenge in federal funding is that applicants often focus heavily on scientific alignment while treating submission mechanics as administrative details. Clinical trial eligibility sits directly at the intersection of both.
A company developing a therapeutic, medical device, diagnostic, or other regulated technology may spend months refining aims, assembling partnerships, and preparing commercialization plans. If the selected Institute or Center does not accept clinical trials under the Parent NOFO, none of that work reaches peer review. The application can be screened out before reviewers ever evaluate the underlying innovation.
That outcome is particularly frustrating because it often stems from choosing the wrong funding path rather than pursuing the wrong science.
This Does Not Mean Clinical Trials Are Off the Table
Applicants should not interpret this policy as NIH broadly moving away from clinical trial funding. Many NIH Institutes continue to accept clinical trials under the Parent NOFOs, and others maintain dedicated funding opportunities specifically designed for clinical research.
The key question is not whether your project includes a clinical trial. The key question is whether the specific organization whose mission aligns with your technology permits clinical trials through this mechanism.
That distinction often determines whether an applicant should pursue the Parent NOFO, identify an alternative solicitation, or engage with program staff before submission.
Organizations preparing clinical-stage proposals may benefit from examining their funding strategy through the same lens reviewers and program officials will use when assessing responsiveness.
Why This Matters for Commercialization-Focused Companies
Many NIH SBIR and STTR applicants eventually reach a point where human subjects work, validation studies, or clinical investigations become necessary to advance the technology. As programs become more complex and agency-specific requirements continue to diverge, applicants can no longer assume that a broadly eligible project will fit every funding opportunity carrying the SBIR or STTR label.
The strongest submission strategies increasingly begin with understanding agency intent, not just project readiness. Clinical trial restrictions are one example of how that intent is expressed through eligibility language that can easily be overlooked.
Applicants who understand those boundaries early can make more informed decisions about timing, solicitation selection, and overall commercialization planning. Those decisions often shape outcomes long before peer review begins.
As NIH continues refining its SBIR and STTR programs, careful attention to responsiveness requirements may become just as important as scientific merit itself.